BPC-157 & TB-500 vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500
Known as the 'Wolverine Stack,' this popular combination pairs two powerful healing peptides. BPC-157 and TB-500 work synergistically to promote tissue repair, reduce inflammation, and accelerate recovery from injuries.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 | LL-37 (Cathelicidin) |
|---|---|---|
| Mechanism | BPC-157 upregulates growth factor expression and promotes angiogenesis, while TB-500 promotes cell migration and differentiation through actin regulation. Together, they enhance wound healing, reduce scar tissue formation, and support musculoskeletal recovery through complementary pathways. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | Typical research protocols: BPC-157 at 250-500mcg daily combined with TB-500 at 2-2.5mg twice weekly during loading phase, then 2mg every 2 weeks for maintenance. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Both peptides administered via subcutaneous injection. Some protocols suggest injecting near injury sites for localized effects. Can be injected separately or as a pre-mixed blend. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Generally well-tolerated. May include mild nausea, temporary fatigue, headache, or localized irritation at injection sites. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |
What They Have in Common
Both BPC-157 & TB-500 and LL-37 (Cathelicidin) are commonly used for: